Physician profile
Michael Snyder
NPI 1932239142
$283,787.84
in general payments reported to CMS, 2019-2025
30 companies · $61K in 2025
The $61K reported for 2025 was more than what 97% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116 · 2020: $22K · 2021: $59K · 2022: $58K · 2023: $47K · 2024: $37K · 2025: $61K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $132K · Food and Beverage: $7,718 · Travel and Lodging: $2,862 · Consulting Fee: $2,440 · Education: $36.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $131,720.83 |
| Food and Beverage | $7,717.99 |
| Travel and Lodging | $2,861.62 |
| Consulting Fee | $2,440.00 |
| Education | $36.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $211,574.76 | 2020-2025 | Ubrelvy, Qulipta, Botox |
| Allergan, INC. | $37,598.99 | 2019-2021 | |
| Pfizer INC. | $32,438.42 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $195.13 | 2025 | |
| Livanova USA, INC. | $177.03 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Janssen Pharmaceuticals, INC | $175.85 | 2023 | Spravato |
| Axsome Therapeutics, INC. | $140.32 | 2025 | Symbravo |
| Nevro Corp. | $138.67 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $134.57 | 2025 | |
| Lilly USA, LLC | $126.04 | 2023-2025 | Emgality, Kisunla, Reyvow |
| Travere Therapeutics, INC. | $123.24 | 2024 | |
| Sk Life Science, INC. | $111.91 | 2022 | |
| Genzyme Corporation | $111.30 | 2022 | |
| Lundbeck LLC | $89.42 | 2022-2025 | Vyepti |
| Amgen INC. | $89.30 | 2023-2024 | Tezspire, Aimovig |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $69.77 | 2025 | Crexont |
| Ucb, INC. | $62.10 | 2025 | Rystiggo, Nayzilam |
| Ipsen Biopharmaceuticals, INC | $61.27 | 2023-2025 | Dysport |
| Biohaven Pharmaceutical Holding Company LTD. | $51.43 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.10 | 2023-2024 | Takhzyro |
| Eisai INC. | $43.94 | 2025 | |
| Acadia Pharmaceuticals INC | $41.61 | 2025 | Nuplazid, Daybue |
| Csl Behring | $33.93 | 2023 | Hizentra |
| Merz Pharmaceuticals, LLC | $27.31 | 2025 | Xeomin |
| Fidia Pharma USA INC. | $25.92 | 2024 | Hymovis |
| Grifols USA, LLC | $22.53 | 2025 | Gamunex-C |
| Impel Pharmaceuticals INC. | $22.02 | 2023 | Trudhesa |
| Argenx US, INC. | $20.01 | 2024 | Vyvgart |
| Tg Therapeutics, INC. | $18.88 | 2025 | |
| Sumitomo Pharma America, INC. | $13.07 | 2024 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.